Johanne Kaplan - 03 Feb 2026 Form 4 Insider Report for ProMIS Neurosciences Inc. (PMN)

Role
Chief Development Officer
Signature
/s/ Max A. Milbury, Attorney in Fact for Johanne Kaplan
Issuer symbol
PMN
Transactions as of
03 Feb 2026
Net transactions value
+$24,988
Form type
4
Filing time
05 Feb 2026, 20:40:29 UTC
Previous filing
24 Sep 2025
Next filing
23 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kaplan Johanne Chief Development Officer C/O PROMIS NEUROSCIENCES INC., 1920 YONGE STREET, SUITE 200, TORONTO, ONTARIO, CANADA /s/ Max A. Milbury, Attorney in Fact for Johanne Kaplan 05 Feb 2026 0001967717

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PMN Common Shares Award $24,988 +2,060 +817% $12.13 2,312 03 Feb 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PMN Warrants to purchase Common Shares Award +2,060 2,060 03 Feb 2026 Common Shares 2,060 $14.40 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 2,060 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 2,060 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.
F2 Reflects a one-for-twenty-five reverse split of the Company's Common Shares effected on November 28, 2025.
F3 The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.